Liam Ratcliffe
Managing Director @ New Leaf Venture Partners
New York, United States
Liam Ratcliffe is a General Partner at New Leaf Venture Partners, and concentrates on biopharmaceutical investing. Liam joined New Leaf in September 2008. He is currently on the board of directors of Afferent Pharmaceuticals Inc, Array BioPharma Inc. (ARRY), Calchan Holdings Ltd., Convergence Pharmaceuticals Ltd, and Neuronetics Inc. Liampreviously served as Senior Vice President and Development Head for Pfizer Neuroscience, as well as Worldwide Head of Clinical Research and Development. Additional positions during his 12 years at Pfizer included Vice President of Exploratory Development for the Mid West region (based in Ann Arbor, MI), and Head of Experimental Medicine at Pfizer’s Sandwich, UK Laboratories. As Head of Neurosciences, Liam was responsible for the development of several successful late-stage projects and marketed products, including Lyrica, Chantix and Geodon. Liam began his career in the pharmaceutical industry in a medical marketing role at Roche in South Africa. He received his M.D. degree and Ph.D. degree in immunology from the University of Cape Town and his M.B.A. degree from the University of Michigan. Liam completed his internal medicine training and fellowship in Immunology at Groote Schuur Hospital and associated teaching hospitals in Cape Town, South Africa.
- Total investments:
- 17
- Last investment:
- Lead investor:
- 35%
Last updated:
For AI agents: llms.txt
Industries Liam Ratcliffe invests in
Stages Liam Ratcliffe invests in
Countries Liam Ratcliffe invests in
Investment Focus
Industry
- Biotechnology 10 (59%)
- Health Care 7 (41%)
- Therapeutics 7 (41%)
- Pharmaceutical 4 (24%)
- Medical 3 (18%)
Stage
- Series A 6 (35%)
- Series B 6 (35%)
- Series C 2 (12%)
- Seed 1 (6%)
- Pre-Seed 1 (6%)
Country
- United States 10 (59%)
- India 1 (6%)
- Australia 1 (6%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Draig Therapeutics
|
Draig Therapeutics is a clinical-stage biopharmaceutical startup dedicated to creating next-generation treatments for serious neuropsychiatric illnesses. | $140M / Series A / Jun 18, 2025 | |
Climb Bio
|
Eliem Therapeutics is a clinical-stage biotechnology company developing treatments for nervous system disorders. The company leverages its expertise in neuroscience, translational medicine, and clinical development to meet this unmet medical need with a highly innovative pipeline.Eliem Therapeutics develops and commercializes potentially“best-in-class” drug candidates to treat neuronal excitability disorders. These conditions—such as chronic pain, depression, epilepsy, and anxiety—cause deep suffering for tens of millions of people each day. At its core, the Eliem team is motivated by the promise of helping patients live happier, more fulfilling lives. | $60M / Series B / May 24, 2021 | |
|
Climb Bio
|
Eliem Therapeutics is a clinical-stage biotechnology company developing treatments for nervous system disorders. The company leverages its expertise in neuroscience, translational medicine, and clinical development to meet this unmet medical need with a highly innovative pipeline.Eliem Therapeutics develops and commercializes potentially“best-in-class” drug candidates to treat neuronal excitability disorders. These conditions—such as chronic pain, depression, epilepsy, and anxiety—cause deep suffering for tens of millions of people each day. At its core, the Eliem team is motivated by the promise of helping patients live happier, more fulfilling lives. | $80M / Series A / Mar 25, 2021 | |
Shoopy
|
Shoopy is an e-commerce platform that automates online and offline sales. Shoopy provides everything needed to start selling online, including a user-friendly interface, customizable design options, marketing and promotional tools, mobile responsive design, inventory management, analytics, and reporting. Users can process in-store sales and trackinventory levels in real-time with Shoopy's POS system. The platform also includes tools for tracking and managing stock levels online and in-store, as well as setting up low-stock alerts. | $250K / Seed / Feb 01, 2021 | |
Passage Bio
|
Passage Bio is a fully integrated gene therapy company with a mission to develop a portfolio of five life-transforming AAV-delivered therapeutics for the treatment of rare monogenic central nervous system diseases. The company is based in Philadelphia, PA and has a research, collaboration and license agreement with the University of Pennsylvaniaand its Gene Therapy Program (GTP) as well as the Orphan Disease Center (ODC). Pursuant to the research collaboration, GTP conducts IND-enabling preclinical work, and Passage Bio is responsible for clinical development, regulatory, manufacturing and commercialization of all product candidates. The ODC is responsible for natural history studies, KOL engagement, and patient advocacy outreach. | $110M / Series B / Sep 04, 2019 | |
|
Passage Bio
|
Passage Bio is a fully integrated gene therapy company with a mission to develop a portfolio of five life-transforming AAV-delivered therapeutics for the treatment of rare monogenic central nervous system diseases. The company is based in Philadelphia, PA and has a research, collaboration and license agreement with the University of Pennsylvaniaand its Gene Therapy Program (GTP) as well as the Orphan Disease Center (ODC). Pursuant to the research collaboration, GTP conducts IND-enabling preclinical work, and Passage Bio is responsible for clinical development, regulatory, manufacturing and commercialization of all product candidates. The ODC is responsible for natural history studies, KOL engagement, and patient advocacy outreach. | $115.5M / Series A / Feb 15, 2019 | |
CuraSen Therapeutics
|
CuraSen Therapeutics is a biotechnology company. | $54.5M / Series A / Oct 17, 2018 | |
Arvinas
|
Arvinas is a pharmaceutical company that focuses on developing novel therapeutics to treat a variety of diseases including cancer, pro-inflammatory, autoimmune and rare diseases. Its proprietary approach is the targeting of disease-causing proteins for degradation thus eliminating them from the body. | $55M / Series C / Apr 04, 2018 | |
Aptinyx
|
Aptinyx Inc. is a biopharmaceutical company discovering and developing innovative therapies for challenging disorders of the brain and nervous system. Aptinyx has a proven platform for discovering proprietary compounds that work through a novel mechanism: modulation of the NMDA receptor to enhance pathways involved with nerve cell communication.This mechanism has applicability across a number of CNS disorders. Our goal is to rapidly advance our most promising drug candidates into clinical development for indications with high unmet medical need. | $70M / Series B / Dec 18, 2017 | |
Neuronetics
|
Neuronetics is focused on developing non-invasive therapies for psychiatric and neurological disorders using MRI-strength magnetic field pulses. They are the first and only company to have a non-systemic and non-invasive depression treatment cleared by the FDA for patients who have not benefited from prior antidepressant treatment. | $15M / Series G / Jun 06, 2017 | |
| See all 17 investments → | |||
Co-Investors
About New Leaf Venture Partners
New Leaf Venture Partners is a venture capital firm that invests primarily in healthcare technology. The company typically focuses on later stage biopharmaceutical products, early stage medical devices, and laboratory infrastructure technologies.The New Leaf Ventures (NLV) team has been built over a decade, originating within Sprout Group, theventure capital affiliate of Credit Suisse First Boston. Sprout Group was formed in 1969 and has historically been one of the leading venture capital firms in the country. The team started to invest in healthcare technology in 1993 and since then, has become a leading venture investor in that sector. In 2005, the entire healthcare technology team of Sprout spun out into NLV.
New Leaf Venture Partners Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Craig Slutzkin
CFO & COO
|
|||
James Niedel
Managing Director
|
|||
|
Liam Ratcliffe
Managing Director
|
|||
Ronald Hunt
Managing Director
|
|||
Vijay Lathi
Managing Director
|
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar stage
Recommended lists
FAQ
What does Liam Ratcliffe invest in?
Liam Ratcliffe invests primarily in Biotechnology, Health Care and Therapeutics startups, most often at Series A and Series B stage. Most of the 17 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
When did Liam Ratcliffe last invest?
The most recent investment recorded for Liam Ratcliffe closed in Jun 2025. Shizune tracks 17 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
